Study of AML classification in Middle Eastern and North African adults
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well the 2022 European LeukemiaNet (ELN) guidelines work for adults of Middle Eastern or North African descent who are newly diagnosed with AML. It aims to improve treatment decisions based on your genetic profile and ancestry.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed acute myeloid leukemia (AML).
- You are at least 18 years old.
- You are of Middle Eastern or North African descent.
- Your HLA type (blood marker for transplant matching) is more than 50%.
- Your physical condition is good enough to be scored 0, 1, 2, or 3 on a standard activity scale.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
This study looks at patients with diffuse large B-cell lymphoma (DLBCL) in the Middle East and Africa. It aims to understand how the disease is treated, what treatments are available, and how patients access newer therapies. You simply continue your regular care and the study team collects information.
Hear when a new Leukemia, Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.